Indication

Dermatomyositis

Dermatomyositis is a rare, immune-mediated inflammatory myopathy characterized by systemic involvement primarily affecting the striated skeletal muscles and the skin. Read more about Dermatomyositis

5 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Dermatomyositis therapies.

Showing 1–5 of 5 drugs

Filter & compare in the drug finder →Opens the drug finder with Dermatomyositis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Dermatomyositis.

Dermatomyositis is a rare, immune-mediated inflammatory myopathy characterized by systemic involvement primarily affecting the striated skeletal muscles and the skin.

It presents across both pediatric and adult populations, clinically marked by progressive, symmetric proximal muscle weakness alongside distinct cutaneous eruptions such as a violaceous heliotrope rash and Gottron papules.

Pathophysiologically driven by immune complex deposition, microvascular endothelial injury, and type I interferon pathway activation, the disease can also involve extra-muscular systems, frequently causing interstitial lung disease, esophageal dysmotility, and cardiac complications, and it carries an elevated association with underlying malignancies in adults.

Personalize your experience

Follow Dermatomyositis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it